相关实验视频

Updated: May 12, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.4K

严重预处理的耐火扩散大B细胞淋巴瘤成功用epcoritamab治疗:案例报告

Jeremy Rosiecki1, Natalie Wallace1, Katelyn Kammers2

  • 1Alaska Oncology and Hematology, Alaska Regional Hospital, Anchorage, AK, USA.

Case reports in oncology
|June 17, 2025
PubMed
概括

埃普科里塔马布为复发性或耐火性扩散性大B细胞淋巴瘤 (DLBCL) 的患者提供了一种新的治疗选择,这些患者没有对其他疗法,包括CAR T细胞疗法,做出反应. 这种双特异性抗体在一个具有挑战性的病例中表现出有效性,为难以治疗的DLBCL改善结果提供了希望.

关键词:
双特异性T细胞参与者.案例报告案例报告化学抗原受体T细胞治疗非霍奇金淋巴瘤非霍奇金淋巴瘤

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...